slides · global inventory
Compare Peers
Slide function collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 9,820
Current window 7,111-7,140
Pages 328
Rows per page 30
Slide function
7,111-7,140 of 9,820
23
Uses a visual timeline/comparison to contrast current standard of care with the proposed product.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
24
The slide uses a bar chart to show benchmark data alongside a specific exposure-response analysis for vedolizumab.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
27
The slide uses peer benchmarking to justify valuation growth expectations based on clinical trial phases.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
28
The table highlights the competitive positioning of SPY001, specifically emphasizing its subcutaneous administration profile.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
31
The chart uses a color-coded safety gradient on the Y-axis and efficacy percentages on the X-axis.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
32
The slide uses a checkmark-based comparison matrix to highlight SPY002's superior profile.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
34
The slide uses a cross-trial comparison to argue that the superiority of one mechanism over the other is not yet established, supporting a redundant development strategy.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
40
The slide uses a bar chart to illustrate the additive effect of combining two therapies, with a supporting table for N, maintenance remission, and safety.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
41
The slide uses a comparison framework to highlight the competitive advantage of Spyre's gut-selective approach.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
49
The slide uses a custom bar chart visualization within a table to show market cap ranges (Min, IPO, Today, Max).Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
50
The table maps historical M&A deal values to Spyre's internal pipeline milestones.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
21
The slide uses a bar chart to compare S&M/GBV ratios and two smaller bar charts to show internal financial performance metrics.Freightos | Investor Presentation Deck | 33 slides · Freightos
Pitch deck Investor relations 1 hit
08
The slide uses a comparison table to justify a portfolio disposal strategy by showing improved quality metrics in the remaining assets.Hipgnosis Songs Fund | Results Presentation Deck | 22 slides · Hipgnosis Songs Fund
Activist deck Investor relations Beat · Solution (Provide relief)Loop · Before After1 hit
07
The table uses a traffic light system (green, yellow, red) to visually indicate performance across categories.Hyperfine | Investor Presentation Deck | 22 slides · Hyperfine
Pitch deck Investor relations Beat · Market Size1 hit
08
The slide uses a comparison framework to contrast traditional vs. new product workflows.Hyperfine | Investor Presentation Deck | 22 slides · Hyperfine
Pitch deck Investor relations Beat · Market Size1 hit
06
The slide uses a visual comparison to highlight the safety advantage of NXC-201, specifically focusing on neurotoxicity and CRS duration.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Interest1 hit
10
The slide uses a comparative timeline/chart layout to contrast clinical outcomes of three different therapies.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · InterestLoop · Aha Moment1 hit
13
Includes extensive source citations in the footer.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Interest1 hit
14
The slide uses a table structure to contrast treatment outcomes and patient growth across three stages of multiple myeloma.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Interest1 hit
15
The slide uses a visual comparison to highlight a 67% improvement in response rates for NXC-201 compared to competitors.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Interest1 hit
24
The slide uses a red dashed box to highlight the primary efficacy metrics (response rates).Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Interest1 hit
26
The slide uses a comparison table framework to highlight competitive advantage in clinical metrics.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Interest1 hit
30
The slide highlights specific safety metrics (CRS and ICANS) for two dosage groups (100x10^6 and 300x10^6 cells).Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Desire1 hit
41
The slide uses a scatter plot to map clinical trial outcomes (mPFS vs. prior lines of therapy) and a table to detail standard-of-care performance across lines of therapy.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Desire1 hit
56
Highlights NXC-201's lower fludarabine dose and Carvykti's longer infusion window.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action1 hit
58
The slide uses a bar chart comparison to benchmark existing market leaders against placebo outcomes.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action1 hit
16
The slide contrasts a large incumbent's metrics with the company's own USP.Nemaura Medical | Investor Presentation Deck | 22 slides · Nemaura Medical
Pitch deck Investor relations Beat · Competition1 hit
14
The table uses a color-coded legend for 'Degree of preference' (High, Medium, Low).Neumora Therapeutics | IPO Presentation Deck | 32 slides · Neumora Therapeutics
Pitch deck Investment bank 1 hit
20
The table compares key metrics like EC50, half-life, brain:plasma ratio, selectivity, bioavailability, and molecular weight.Neumora Therapeutics | IPO Presentation Deck | 32 slides · Neumora Therapeutics
Pitch deck Investment bank 1 hit
11
Peer group defined as commercial insured banks with assets between $3-10 billion.Pathward Financial | Investor Presentation Deck | 23 slides · Pathward
Pitch deck Investor relations Beat · FinancialsLoop · Cost Of Inaction1 hit